Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH and the Company began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is actively pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris, and interest about Soliris in the patient, physician and payor communities. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... DALLAS , September 23, 2014 ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to ... Market over the forecast period of 2014 to ... Billion by 2019, at CAGR of 9.6% from ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary focus on ... C. Shrotriya , MD, Chairman and Chief Executive Officer ... The appointment was made in connection with the recently ...
(Date:9/23/2014)... Sept. 23, 2014 Today, DripDrop, the first ... formation of the DripDrop Foundation, with its primary ... worldwide. Utilizing scientific advancements in Oral Rehydration Therapy ... reduce dehydration and healthcare costs through strategic partnerships, ... "DripDrop has been used in disaster ...
Breaking Medicine Technology:Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4DripDrop Forms Foundation To Scale Relief Efforts 2
... Dec. 3, 2010 Sermo ( http://www.sermo.com ), the ... free Sermo Report titled, " Potential Replacements for Coumadin ... awareness and understanding of these products and potential barriers ... were aware that a new product, Pradaxa (dabigatran etexilate ...
... 3, 2010 VIVUS, Inc. (Nasdaq: ... present an overview of the company at two ... presentation schedule is as follows:Canaccord Genuity Cardiovascular, Diabetes ... PTNikko Hotel, San Francisco, CAPresenter: Charles Bowden, MD, ...
Cached Medicine Technology:Sermo Study shows 70% of Specialists are Ready to Replace Warfarin 2
(Date:9/23/2014)... The U.S. Pharmacopeial Convention (USP) has submitted ... (WHO) regarding the assignment of Biological Qualifiers (BQ) to ... Expert Group of the Programme of International Nonproprietary Names ... naming of all biologicals that is consistent with existing, ... these drugs. , Hence, USP supports the concept ...
(Date:9/23/2014)... Dotinga HealthDay Reporter MONDAY, Sept. ... four out of five heart attacks in men, a new study ... to have heart attacks over an average of 11 years if ... diet, exercise and weight fronts, the study found. Only ... this ultra-healthy-living category. But they were 86 percent less likely to ...
(Date:9/23/2014)... California (PRWEB) September 23, 2014 With ... items, World Gardens Café has added Vegan as an ... come fully prepared and frozen – perfect for busy ... as a fast food meal, these healthy alternatives are ... menu includes meals such as Adobe Tempeh, Caribbean Vegetable ...
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 Fountain Valley ... has won their latest body transformation contest and been named ... “Jennifer was raised here in Fountain Valley and still resides ... since June 2014 and she recently signed up for one ... been phenomenal,” says owner Zenia Joyner. “In just six weeks, ...
(Date:9/23/2014)... Recently, Best Cheap Hosting USA, a popular review ... best VPS hosting suppliers in the current market. Among ... hosting is a very popular. The account owner is ... others’ websites under his name, brand or company. , ... primary hosting plans (reseller hosting and low cost shared ...
Breaking Medicine News(10 mins):Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:Study: Healthy Lifestyle Behaviors May Prevent 80 Percent of Heart Attacks 2Health News:Study: Healthy Lifestyle Behaviors May Prevent 80 Percent of Heart Attacks 3Health News:World Gardens Café Announces Launch of New Vegan Menu 2Health News:Fountain Valley Fit Body Boot Camp Announces Winner of Fitness Boot Camp Ambassador Contest 2Health News:Best Cheap Hosting USA: Bluehost And JustHost Are Ranked As The Best VPS Hosting Suppliers 2
... of the wellbeing and inclusion of former politically motivated ... University today (Monday 14 March). Ageing and ... Ireland and the border region of Ireland investigated the ... and republican former prisoners (aged 50 and over) as ...
... (March 14, 2011) Research has shown that playing a ... children, but playing a used instrument also can pose a ... instruments were found to be heavily contaminated with a variety ... minor to serious infectious and allergic diseases, according to a ...
... , MONDAY, March 14 (HealthDay News) -- Watching this year,s ... for those who bet on the games, one expert suggests. ... sites and spoiler message boards seems to suggest that predicting ... according to Stephen M. Nowlis, a marketing professor at the ...
... numerous paths to resist the targeted drug Herceptin, but ... a tumor,s vulnerability to treatment, scientists at The University ... at Nature Medicine . Adding the drug ... cutting off at least five different molecular pathways, each ...
... March 11 (HealthDay News) -- People would prefer to allow ... they know others are watching, says a new study. ... think badly of them if they do something wrong rather ... research in the journal Psychological Science . "Omissions ...
... (HealthDay News) -- A doctor,s empathy can improve the care ... of being a good doctor, according to a new study. ... 2006 and June 2009 by 29 doctors at Thomas Jefferson ... of empathy for patients, while the quality of patient care ...
Cached Medicine News:Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:Is your child's hobby making him sick? 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3Health News:When Someone Is Watching, You're Less Inclined to Do Bad Things 2
Whether you require high flow rates for critical situations or lower rates for others, this insufflator handles both situations equally well, regulated by the preselected pressure....
The TurboFlow 8000 has two separate gas output ports which, unlike many high flow insufflators, use standard-size tubing, each capable of providing up to 20 LPM flow....
Tongs...
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
Medicine Products: